IRIS
CRETELLA, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.412
AS - Asia 1.746
EU - Europa 1.312
SA - Sud America 271
AF - Africa 87
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.834
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.364
SG - Singapore 579
CN - Cina 491
IT - Italia 337
VN - Vietnam 285
IE - Irlanda 219
BR - Brasile 210
SE - Svezia 201
HK - Hong Kong 130
DE - Germania 118
FI - Finlandia 118
FR - Francia 63
ZA - Sudafrica 59
IN - India 57
NL - Olanda 45
GB - Regno Unito 44
AT - Austria 36
TR - Turchia 36
BD - Bangladesh 33
BE - Belgio 32
AR - Argentina 27
CA - Canada 25
RU - Federazione Russa 21
JP - Giappone 19
ID - Indonesia 18
PL - Polonia 17
MX - Messico 16
UA - Ucraina 15
CZ - Repubblica Ceca 12
ES - Italia 12
IQ - Iraq 12
KR - Corea 11
CI - Costa d'Avorio 10
CO - Colombia 10
EC - Ecuador 10
PK - Pakistan 10
PH - Filippine 8
SA - Arabia Saudita 7
UZ - Uzbekistan 7
LT - Lituania 6
TH - Thailandia 6
TN - Tunisia 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
IR - Iran 4
JO - Giordania 4
KG - Kirghizistan 4
AZ - Azerbaigian 3
CL - Cile 3
EG - Egitto 3
JM - Giamaica 3
LB - Libano 3
LU - Lussemburgo 3
QA - Qatar 3
SY - Repubblica araba siriana 3
AL - Albania 2
BB - Barbados 2
BO - Bolivia 2
CH - Svizzera 2
DZ - Algeria 2
HU - Ungheria 2
KE - Kenya 2
MA - Marocco 2
MY - Malesia 2
OM - Oman 2
PE - Perù 2
RO - Romania 2
AO - Angola 1
BW - Botswana 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PY - Paraguay 1
RS - Serbia 1
TG - Togo 1
TW - Taiwan 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.834
Salva come PNG Salva come JPEG
Città #
Singapore 321
Ashburn 255
Chandler 246
Ann Arbor 240
Dublin 219
Dallas 217
San Jose 148
Parma 135
Santa Clara 127
Hong Kong 121
Beijing 92
Dearborn 85
Ho Chi Minh City 84
Boardman 64
Hanoi 59
New York 57
Johannesburg 55
Los Angeles 54
Munich 54
Shanghai 53
Council Bluffs 50
Nanjing 40
Princeton 35
Lauterbourg 33
Izmir 32
Vienna 31
Bremen 27
Helsinki 23
Brussels 21
Wilmington 21
Shenyang 20
Nanchang 19
Haiphong 17
Jinan 17
São Paulo 17
Buffalo 16
Hebei 16
Kunming 16
Redmond 16
Woodbridge 15
Columbus 14
Des Moines 14
Hefei 14
Jakarta 14
San Mateo 14
Tokyo 14
Toronto 14
Frankfurt am Main 12
Pune 12
Wayne 12
Bologna 11
Denver 11
Modena 11
Tianjin 11
Abidjan 10
Chennai 10
Jiaxing 10
Norwalk 10
Phoenix 10
Seattle 10
Turku 10
Warsaw 10
Guangzhou 9
Houston 9
New Delhi 9
Rio de Janeiro 9
Dong Ket 8
Jacksonville 8
London 8
Manchester 8
Rio Saliceto 8
Rome 8
Stockholm 8
The Dalles 8
Binche 7
Brno 7
Brooklyn 7
Fremont 7
Baghdad 6
Boston 6
Brescia 6
Changsha 6
Chicago 6
Da Nang 6
Fuzhou 6
Genoa 6
Milan 6
Moscow 6
Orem 6
Poplar 6
Tashkent 6
Belo Horizonte 5
Brasília 5
Leawood 5
Nuremberg 5
Redwood City 5
Seoul 5
Amman 4
Atlanta 4
Bishkek 4
Totale 3.674
Salva come PNG Salva come JPEG
Nome #
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 251
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 215
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 211
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 201
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 201
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 197
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 193
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 192
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 185
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 182
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 180
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 175
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 174
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 171
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 171
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 170
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 158
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 158
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 158
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 153
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 151
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 140
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 139
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 139
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 136
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 134
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 132
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 128
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 124
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) 120
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 120
CDK4/6 inhibitors in HER2-positive breast cancer 120
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 112
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 111
T-DM1: a new therapeutic approach in HER-2 overexpressing NSCLC cell lines 105
Targeting FGFR1 pathway in squamous cell lung cancer 98
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition 72
Combined use of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) as target therapy in non-small cell lung cancer (NSCLC) 1
Totale 5.941
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.110
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.110
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202136 0 0 0 0 0 0 0 0 0 0 0 36
2021/2022232 28 12 21 14 4 3 30 10 10 12 11 77
2022/2023877 80 107 61 69 82 102 4 57 261 3 40 11
2023/2024337 21 30 2 15 31 78 35 28 13 23 22 39
2024/20251.000 19 39 51 69 113 110 86 49 138 70 85 171
2025/20262.328 222 192 269 254 324 137 207 82 333 181 94 33
Totale 5.941